Janux Therapeutics, Inc. (JANX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Janux Therapeutics, Inc. (JANX) closed at USD 17.13 on 2026-10-14, a change of -42.4 % over the past year, with a market capitalization of USD 1.06B.

Janux Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Janux Therapeutics, Inc. key figures

Previous close

USD 17.13 (2026-10-14)

1-year change

-42.4 %

Market cap

USD 1.06B

Enterprise value

USD 108.97M

P/E ratio (trailing)

-10.50

P/E ratio (forward)

-6.60

EPS (trailing)

-1.65

EPS (forward)

-2.62

PEG ratio

n/a

Price to book

1.14

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

5.77

Employees

113

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Janux Therapeutics, Inc.

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. It also develops JANX011, a CD19-targeted adaptive immune response modulator that is in phase 1 clinical study developed for autoimmune diseases. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates; and Bristol Myers Squibb to develop and commercialize an undisclosed, novel tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Janux Therapeutics, Inc. and compare it with other stocks.